Cure8 news brief
This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may affect patients' ability to get and stay on recommended care.
Early-stage studies (epigenetics, device patches, diet trials) point to possible future tools but are not immediate treatment changes.
People with IBD and their caregivers, clinicians who treat IBD, and researchers following IBD genetics, biomarkers, or digital monitoring technologies.
The article is an event preview summarizing many early or conference-presented findings rather than reporting full peer-reviewed results. Key topics include access and cost barriers (insurance, step therapy), epigenetic research using IBD Plexus data, and real-world gaps in completing treat-to-target monitoring (endoscopy and fecal calprotectin).
The release states that abstracts will be published in supplements to Gastroenterology and Inflammatory Bowel Diseases and that data were embargoed until the meeting start.
If you want details: look for the individual abstracts or subsequent peer-reviewed papers; the press release provides contact emails and says all abstracts are available through the meeting and journal supplements.
This is a conference preview summarizing multiple abstracts and survey results; details, methods, and full data are not reported here. Abstracts are embargoed until the meeting and will be published as supplements—read those original abstracts or later peer-reviewed papers for full methods and results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...
A test that more accurately predicts which IBD patients with pre-cancerous bowel changes will develop cancer could help target surveillance and treatment to those at higher risk and reduce unnecessary procedures for...
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
